Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial Meeting Abstract
| Authors: | Atkins, M. B.; Escudier, B.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C.; George, S.; Powles, T.; Donskov, F.; Kollmannsberger, C. K.; Grimm, M. O.; Tomita, Y.; Rini, B. I.; Jiang, R.; Federov, V.; Lee, C. W.; Desilva, H.; Tannir, N. M.; Motzer, R. J. |
| Abstract Title: | Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial |
| Meeting Title: | 6th Kidney Cancer Research Summit (KCRS 2024) |
| Keywords: | ipilimumab; nivolumab; checkmate 214; advanced rcc; favorable risk |
| Journal Title: | The Oncologist |
| Volume: | 29 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Jul 11-12 |
| Meeting Location: | Boston, MA |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S17 |
| End Page: | S18 |
| Language: | English |
| ACCESSION: | WOS:001289325400049 |
| DOI: | 10.1093/oncolo/oyae181.026 |
| PROVIDER: | wos |
| PMCID: | PMC11301908 |
| Notes: | Meeting Abstract: 8 -- Abstract citation ID: oyae181.026 -- Meeting also took place virtually -- Source: Wos |
